

REACTION OF *N*-TOSYLATED IMINES WITH α,β -ACETYLENIC KETONES VIA ORGANOZINC SPECIES

Yong-Kang Liu,¹ Quan-Ping Wu,² Qing-Xiang Guo,¹
and Song Xue²

¹Department of Chemistry, University of Science and Technology of China,
Hefei, China

²Department of Applied Chemistry, Tianjin University of Technology,
Tianjin, China

A new procedure for stereoselective synthesis of trisubstituted alkenes by an one-pot, three-component reaction of N-tosylated imines with α,β -acetylenic ketones and organozinc species $\text{CF}_3\text{COOZnEt}$ was described. This reaction system provides β -branched Morita–Baylis–Hillman adducts with excellent yields in absence of any catalyst.

Keywords: α,β -Acetylenic ketones; $\text{CF}_3\text{COOZnEt}$; *N*-tosylated imines; trisubstituted alkenes


INTRODUCTION

Among the reactions in which C–C bonds are formed, the Morita–Baylis–Hillman reaction (MBH) is one of the most economical and important carbon–carbon bond-forming reactions.^[1,2] The MBH adducts, which are allylic alcohol or allylic amine derivatives, play an important role in bringing latitude to organic synthesis and in the construction of molecular assemblies as useful intermediates.^[3] However, this reaction suffers from slow reaction rates, which limit the scope of substrates.^[4] Many methods to accelerate the reaction rate, such as change in catalyst, irradiation with microwaves, reaction under high pressure, and reaction in ionic liquids, have been developed.^[5–7]

Organozinc reagents have been widely used in the conjugate addition to various reagents.^[8–10] Nevertheless, the reaction of organozinc reagents with α,β -acetylenic ketones has not been reported thus far.^[11,12] Recently, we reported a new procedure for synthesis of β -branched MBH adducts by the reaction of α,β -acetylenic ketones with organozinc species and aldehydes.^[13] In continuation of our interest in exploring the reactivity and behavior of the organozinc species $\text{CF}_3\text{CO}_2\text{ZnR}$ with electrophiles, we wanted to examine reactions of *N*-tosylated imines with α,β -acetylenic ketones and the organozinc species $\text{CF}_3\text{COOZnEt}$. Fortunately, $\text{CF}_3\text{COOZnEt}$ can react with

Received February 21, 2008.

Address correspondence to Song Xue, Department of Applied Chemistry, Tianjin University of Technology, Tianjin 300191, China. E-mail: xuesong@ustc.edu.cn



Scheme 1. The reaction of *N*-tosylated imines with α,β -acetylenic ketones in the presence of $CF_3COOZnEt$.

terminal α,β -acetylenic ketones and *N*-tosylated imines with good yields in absence of any catalyst (Scheme 1). Here we report these results.


RESULTS AND DISCUSSION

Initially, we carried out reactions using different quantities of reagents in CH_2Cl_2 . The best results were obtained with a 1.0:1.5:1.5 ratio of *N*-tosylated imines, α,β -acetylenic ketones, and $CF_3COOZnEt$. Treatment of the in situ-generated CF_3CO_2ZnEt ^[13,14] with 1-phenylprop-2-yn-1-one and *N*-benzylidene-4-methylbenzenesulfonamide in CH_2Cl_2 at room temperature for 10 h generated β -substituted Baylis–Hillman adducts **3a** in 94% isolated yield (entry 1, Table 1). The reaction was performed in diethyl ether and tetrahydrofuran (THF) and gave the desired adducts **3a** in 5% and 21% respectively. Thus, CH_2Cl_2 was the solvent of choice.

With the optimal reaction conditions in hand, a variety of α,β -acetylenic ketones were then allowed to react with *N*-tosylated imines and CF_3CO_2ZnEt . These results are presented in Table 1. Both aliphatic and aromatic acetylenic ketones could be employed. The reaction of aromatic acetylenic ketones with *N*-tosylated imines proceeded smoothly and provided the corresponding products in good yields. The substituents on the benzene ring of aromatic acetylenic ketones seem to have no obvious effect on the yields. However, it should be noted that 1-(4-nitrophenyl)prop-2-yn-1-one provided the desired product **3l** in a moderate yield (52%) at room temperature (Table 1, entry 14), which was due to the high reactivity of the acetylenic ketone, leading to formation of the direct self-condensation product. [The 1,4-conjugate addition of $CF_3COOZnEt$ to α,β -acetylenic ketone generates an allenolate **4** (Scheme 2), which reacts with secondary α,β -acetylenic ketone to form a small amount of self-condensation products as by-products.] When the reaction temperature decreased to 0 °C, the yield of **3l** increased to 64%. Aliphatic α,β -acetylenic ketones, instead of aromatic α,β -acetylenic ketones, can also react with *N*-tosylated imines to provide the β -branched MBH adducts in moderate yields. The poor yields obtained might be ascribed to the lesser reactivity of aliphatic acetylenic ketones than that of aromatic acetylenic ketones. On the other hand, various *N*-tosylated imines were submitted to this reaction, and the corresponding products were obtained in good yields. The substituents on the benzene ring of *N*-tosylated imines seem to have no obvious effect on the yields. The stereochemistry of the β -branched Baylis–Hillman adducts was determined to be *Z* configuration for all cases in our reaction system as revealed by 1H NMR analyses of the crude products. The *E*-isomer of the product was not observed from the 1H and ^{13}C NMR spectra.

Table 1. Reactions of *N*-tosylated imines with α,β -acetylenic ketones and $\text{CF}_3\text{COOZnEt}$

Entry	R ¹	R ²	Product	Yield ^a (%)
1	C ₆ H ₅	C ₆ H ₅	3a	94
2	C ₆ H ₅	C ₆ H ₅	3a	5 ^b
3	C ₆ H ₅	C ₆ H ₅	3a	21 ^c
4	C ₆ H ₅	4-MeC ₆ H ₄	3b	91
5	C ₆ H ₅	4-MeOC ₆ H ₄	3c	90
6	C ₆ H ₅	4-ClC ₆ H ₄	3d	86
7	C ₆ H ₅	CH ₃	3e	75
8	4-MeC ₆ H ₄	C ₆ H ₅	3f	85
9	4-MeC ₆ H ₄	4-MeC ₆ H ₄	3g	84
10	4-MeC ₆ H ₄	4-MeOC ₆ H ₄	3h	81
11	4-MeC ₆ H ₄	4-FC ₆ H ₄	3i	93
12	4-MeC ₆ H ₄	4-ClC ₆ H ₄	3j	89
13	4-MeC ₆ H ₄	4-BrC ₆ H ₄	3k	85
14	4-MeC ₆ H ₄	4-NO ₂ C ₆ H ₄	3l	52 (64) ^d
15	4-MeC ₆ H ₄	CH ₃	3m	73
16	4-MeC ₆ H ₄	C ₆ H ₁₃	3n	78
17	4-MeOC ₆ H ₄	C ₆ H ₅	3o	90
18	4-MeOC ₆ H ₄	4-MeOC ₆ H ₄	3p	88
19	4-MeOC ₆ H ₄	4-BrC ₆ H ₄	3q	86
20	4-MeOC ₆ H ₄	CH ₃	3r	74
21	4-ClC ₆ H ₄	4-MeOC ₆ H ₄	3s	92
22	4-ClC ₆ H ₄	4-FC ₆ H ₄	3t	95
23	2-ClC ₆ H ₄	4-MeC ₆ H ₄	3u	88
24	2-ClC ₆ H ₄	4-BrC ₆ H ₄	3v	87

^aYields after purification by column chromatography.^bPerformed in Et₂O.^cPerformed in THF.^dPerformed at 0 °C.**Scheme 2.** Plausible mechanism for the reaction.

Based on the works of Kitamura et al.^[15] and Taniguchi et al.,^[16] a plausible mechanism of the reaction was proposed, as shown in Scheme 2. The first step of the reaction is the 1,4-conjugate addition of the organozinc species $\text{CF}_3\text{COOZnEt}$ to α,β -acetylenic ketone to form an active allenolate intermediate **4**. The *N*-tosylated imine coordinates with the zinc atom, which serves to orient *N*-tosylated imines for attack on allenolate. Therefore, the steric interaction between *N*-tosylated imine R^1 group and Et at the β -position of the allenolate dominates the stereochemistry of this reaction. The *N*-tosylated imine attacks the allenolate from the less hindered side of the allenolate **4** to provide *Z*-isomer as the product.

In conclusion, an efficient method for the synthesis of functionalized trisubstituted olefins has been developed. The reactions of *N*-tosylated imines with α,β -acetylenic ketones and organozinc species $\text{CF}_3\text{CO}_2\text{ZnEt}$ proceed smoothly in the absence of any catalyst. The procedure can be subjected to aliphatic and aromatic α,β -acetylenic ketones, which affords β -branched MBH adducts in moderate to excellent yields.

EXPERIMENTAL

General Procedure: Reaction of *N*-Tosylated Imines with α,β -Acetylenic Ketones and $\text{CF}_3\text{CO}_2\text{ZnEt}$

CF_3COOH (58 μL , 0.75 mmol) slowly was added dropwise via syringe to a solution of Et_2Zn (80 μL , 0.75 mmol) in 2 mL CH_2Cl_2 at 0°C under N_2 . After stirring for 30 min at 0°C , *N*-tosylated imines (0.5 mmol) were added, and then acetylenic ketone (0.75 mmol) was added. The mixture was stirred for 10 h at room temperature until thin-layer chromatography (TLC) indicated complete consumption of the starting *N*-tosylated imines. The reaction was quenched by saturated aqueous NH_4Cl and extracted with Et_2O ($3 \times 10\text{ mL}$). The combined organic extracts were washed with brine, dried over MgSO_4 , and concentrated under reduced pressure to an oily residue. The desired product was isolated by silica-gel chromatography with petroleum ether/ EtOAc (5:1–3:1).

Spectral Data

Compound 3a. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.80 (t, $J = 7.5\text{ Hz}$, 3H), 1.68–1.80 (m, 2H), 2.42 (s, 3H), 5.26 (d, $J = 7.8\text{ Hz}$, 1H), 5.82 (t, $J = 7.5\text{ Hz}$, 1H), 6.08 (d, $J = 7.8\text{ Hz}$, 1H), 7.17–7.24 (m, 7H), 7.31–7.40 (m, 2H), 7.53 (t, $J = 7.5\text{ Hz}$, 1H), 7.61 (d, $J = 6.9\text{ Hz}$, 2H), 7.73 (d, $J = 8.4\text{ Hz}$, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.5, 23.4, 62.1, 126.9, 127.3, 127.7, 128.56, 128.58, 129.1, 129.5, 133.5, 136.8, 137.6, 137.9, 138.6, 138.8, 143.2, 199.1. IR (neat): 3284, 1648, 1596, 1449, 1330, 1238, 1161 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{18}\text{H}_{18}\text{NO}$ ($\text{M}-\text{Ts}^+$): 264.1388; found 264.1392.

Compound 3b. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.72 (t, $J = 7.5\text{ Hz}$, 3H), 1.64 (m, 2H), 2.33 (s, 3H), 2.34 (s, 3H), 5.19 (d, $J = 7.8\text{ Hz}$, 1H), 5.69 (t, $J = 7.5\text{ Hz}$, 1H), 6.14 (d, $J = 7.8\text{ Hz}$, 1H), 7.12–7.17 (m, 9H), 7.46 (d, $J = 8.1\text{ Hz}$, 2H), 7.66 (d, $J = 8.1\text{ Hz}$, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.2, 21.4, 21.7, 23.3, 62.0, 126.9, 127.2, 127.5, 128.4, 129.2, 129.3, 129.4, 134.9, 136.8, 137.86, 137.92, 138.8,

143.0, 144.5, 198.7. IR (neat): 3285, 3028, 1622, 1604, 1414, 1341, 1162, 1094 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{20}\text{NO}$ ($\text{M}-\text{Ts}^+$): 278.1545; found 278.1541.

Compound 3c. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.80 (t, $J=7.5$ Hz, 3H), 1.70 (m, 2H), 2.41 (s, 3H), 3.75 (s, 3H), 5.21 (d, $J=7.5$ Hz, 1H), 5.82 (t, $J=7.5$ Hz, 1H), 6.03 (d, $J=7.5$ Hz, 1H), 6.74 (d, $J=8.7$ Hz, 2H), 7.12 (d, $J=8.7$ Hz, 2H), 7.22 (d, $J=8.1$ Hz, 2H), 7.38 (t, $J=7.5$ Hz, 2H), 7.53 (d, $J=7.5$ Hz, 1H), 7.65 (d, $J=7.5$ Hz, 2H), 7.71 (d, $J=8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.5, 23.3, 55.2, 61.2, 113.9, 127.2, 128.2, 128.5, 129.1, 129.4, 130.9, 133.4, 137.1, 137.5, 137.8, 138.0, 143.1, 159.0, 199.1. IR (neat): 3283, 1710, 1647, 1596, 1571, 1508, 1455, 1421, 1323, 1258, 1160 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{20}\text{NO}_2$ ($\text{M}-\text{Ts}^+$): 294.1494; found 294.1493.

Compound 3d. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.73 (t, $J=7.5$ Hz, 3H), 1.55–1.70 (m, 2H), 2.34 (s, 3H), 5.22 (d, $J=8.4$ Hz, 1H), 5.76 (t, $J=7.5$ Hz, 1H), 6.13 (d, $J=8.4$ Hz, 1H), 7.09–7.15 (m, 7H), 7.25–7.29 (m, 2H), 7.51 (d, $J=8.7$ Hz, 2H), 7.63 (d, $J=8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.5, 23.4, 61.7, 126.9, 127.2, 127.7, 128.6, 128.9, 129.5, 130.5, 135.8, 136.8, 137.8, 138.3, 138.6, 140.0, 143.2, 197.8. IR (KBr): 3292, 1625, 1588, 1449, 1402, 1340, 1231, 1161 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{18}\text{H}_{17}\text{NOCl}$ ($\text{M}-\text{Ts}^+$): 298.0999; found 298.0994.

Compound 3e. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.94 (t, $J=7.5$ Hz, 3H), 2.07 (s, 3H), 2.22 (m, 2H), 2.39 (s, 3H), 5.15 (d, $J=8.9$ Hz, 1H), 5.65 (d, $J=8.9$ Hz, 1H), 5.73 (t, $J=7.5$ Hz, 1H), 7.28–7.10 (m, 7H), 7.65 (d, $J=8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.7, 21.5, 23.1, 31.9, 61.6, 126.7, 127.3, 127.6, 128.6, 129.5, 138.1, 138.8, 139.1, 142.0, 143.3, 203.2. IR (KBr): 2963, 1656, 1494, 1418, 1330, 1262, 1160 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{13}\text{H}_{16}\text{NO}$ ($\text{M}-\text{Ts}^+$): 202.1232; found 202.1235.

Compound 3f. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.65 (t, $J=7.5$ Hz, 3H), 1.58 (m, 2H), 2.13 (s, 3H), 2.27 (s, 3H), 5.09 (d, $J=7.5$ Hz, 1H), 5.90 (t, $J=7.5$ Hz, 1H), 6.33 (d, $J=7.5$ Hz, 1H), 7.03 (d, $J=8.1$ Hz, 2H), 7.09 (d, $J=8.1$ Hz, 2H), 7.20 (d, $J=8.1$ Hz, 2H), 7.38 (t, $J=7.5$ Hz, 2H), 7.53 (t, $J=7.5$ Hz, 1H), 7.66 (d, $J=7.5$ Hz, 2H), 7.70 (d, $J=8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.1, 21.5, 23.4, 61.7, 126.9, 127.3, 128.6, 129.2, 129.3, 129.5, 133.5, 135.8, 137.0, 137.4, 137.6, 137.9, 138.4, 143.1, 199.1. IR (KBr): 3293, 1623, 1595, 1509, 1425, 1382, 1332, 1156 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{20}\text{NO}$ ($\text{M}-\text{Ts}^+$): 278.1545; found 278.1543.

Compound 3g. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.72 (t, $J=7.5$ Hz, 3H), 1.64 (m, 2H), 2.21 (s, 3H), 2.33 (s, 3H), 2.34 (s, 3H), 5.66 (d, $J=7.8$ Hz, 1H), 5.70 (t, $J=7.5$ Hz, 1H), 6.12 (d, $J=7.8$ Hz, 1H), 6.95 (d, $J=7.8$ Hz, 2H), 7.07–7.12 (m, 6H), 7.50 (d, $J=8.1$ Hz, 2H), 7.65 (d, $J=8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.2, 21.0, 21.4, 21.7, 23.2, 61.7, 126.8, 127.2, 129.1, 129.16, 129.22, 129.3, 135.0, 135.8, 137.0, 137.1, 137.7, 137.9, 143.0, 144.4, 198.6. IR (KBr): 3268, 1626, 1602, 1513, 1427, 1384, 1341, 1262, 1161 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{20}\text{H}_{22}\text{NO}$ ($\text{M}-\text{Ts}^+$): 292.1701; found 292.1694.

Compound 3h. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.80 (t, $J=7.5$ Hz, 3H), 1.63–1.82 (m, 2H), 2.28 (s, 3H), 2.42 (s, 3H), 3.88 (s, 3H), 5.17 (d, $J=7.5$ Hz, 1H),

5.72 (t, $J = 7.5$ Hz, 1H), 6.10 (d, $J = 7.5$ Hz, 1H), 6.85 (d, $J = 8.7$ Hz, 2H), 7.01 (d, $J = 8.1$ Hz, 2H), 7.11 (d, $J = 8.1$ Hz, 2H), 7.22 (d, $J = 8.1$ Hz, 2H), 7.64 (d, $J = 8.7$ Hz, 2H), 7.72 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.0, 21.5, 23.2, 55.5, 61.8, 113.8, 126.8, 127.3, 129.1, 129.4, 130.4, 131.7, 135.8, 137.0, 137.1, 137.2, 137.9, 143.0, 164.0, 197.5. IR (neat): 3428, 1956, 1682, 1493, 1453, 1372, 1212 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{20}\text{H}_{22}\text{NO}_2$ ($\text{M}-\text{Ts}^+$): 308.1651; found 308.1653.

Compound 3i. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.77 (t, $J = 7.5$ Hz, 3H), 1.60–1.75 (m, 2H), 2.23 (s, 3H), 2.37 (s, 3H), 5.13 (d, $J = 7.5$ Hz, 1H), 5.76 (d, $J = 7.5$ Hz, 2H), 5.79 (t, $J = 7.8$ Hz, 2H), 6.95–7.03 (m, 6H), 7.18 (d, $J = 8.1$ Hz, 2H), 7.61–7.68 (m, 4H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.0, 21.5, 23.3, 61.5, 115.6, 115.9, 126.8, 127.3, 129.2, 129.4, 131.8, 132.0, 133.8, 135.6, 137.0, 137.4, 137.8, 143.2, 197.4. IR (neat): 3435, 1683, 1611, 1585, 1512, 1249, 1174 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{19}\text{NOF}$ ($\text{M}-\text{Ts}^+$): 296.1451; found 296.1450.

Compound 3j. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.77 (t, $J = 7.5$ Hz, 3H), 1.58–1.74 (m, 2H), 2.23 (s, 3H), 2.37 (s, 3H), 5.13 (d, $J = 7.5$ Hz, 1H), 5.77 (d, $J = 7.5$ Hz, 1H), 5.80 (t, $J = 7.5$ Hz, 1H), 6.93–7.04 (m, 4H), 7.18 (d, $J = 8.4$ Hz, 2H), 7.30 (d, $J = 8.7$ Hz, 2H), 7.53 (d, $J = 8.7$ Hz, 2H), 7.65 (d, $J = 8.4$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.1, 21.5, 23.4, 61.4, 126.8, 127.3, 128.9, 129.2, 129.3, 129.4, 130.6, 125.6, 136.9, 137.5, 137.8, 138.2, 140.0, 143.2, 197.7. IR (neat): 3298, 1635, 1587, 1509, 1421, 1340, 1231, 1160 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{19}\text{NOCl}$ ($\text{M}-\text{Ts}^+$): 312.1155; found 312.1154.

Compound 3k. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.77 (t, $J = 7.5$ Hz, 3H), 1.70 (m, 2H), 2.23 (s, 3H), 2.37 (s, 3H), 5.13 (d, $J = 7.5$ Hz, 1H), 5.78 (t, $J = 7.5$ Hz, 1H), 5.82 (d, $J = 7.5$ Hz, 1H), 6.97–7.03 (m, 4H), 7.18 (d, $J = 8.1$ Hz, 2H), 7.44–7.49 (m, 4H), 7.65 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.1, 21.5, 23.4, 61.3, 126.8, 127.2, 128.7, 129.3, 129.4, 130.6, 131.9, 135.6, 136.3, 136.9, 137.4, 137.7, 138.2, 143.2, 197.9. IR (neat): 3441, 2923, 1633, 1596, 1505, 1422, 1340, 1227, 1160 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{19}\text{NOBr}$ ($\text{M}-\text{Ts}^+$): 356.0650; found 356.0648.

Compound 3l. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.79 (t, $J = 7.5$ Hz, 3H), 1.66–1.73 (m, 2H), 2.22 (s, 3H), 2.37 (s, 3H), 5.19 (d, $J = 7.5$ Hz, 1H), 5.74 (t, $J = 7.8$ Hz, 1H), 5.97 (d, $J = 7.5$ Hz, 1H), 6.95–6.99 (m, 4H), 7.18 (d, $J = 7.8$ Hz, 2H), 7.65 (d, $J = 7.8$ Hz, 2H), 7.74 (d, $J = 8.4$ Hz, 2H), 8.17 (d, $J = 8.4$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.1, 21.6, 23.6, 61.3, 123.9, 126.8, 127.3, 129.5, 129.6, 130.0, 135.4, 137.0, 137.7, 137.9, 139.6, 142.3, 143.5, 150.5, 197.4. IR (neat): 3234, 2964, 1665, 1560, 1524, 1431, 1345, 1262, 1239, 1158 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_3$ ($\text{M}-\text{Ts}^+$): 323.1396; found 323.1400.

Compound 3m. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.94 (t, $J = 7.5$ Hz, 3H), 2.05 (s, 3H), 2.14 (m, 2H), 2.26 (s, 3H), 2.37 (s, 3H), 5.10 (d, $J = 8.9$ Hz, 1H), 5.65 (d, $J = 8.9$ Hz, 1H), 5.73 (t, $J = 7.5$ Hz, 1H), 6.98–7.01 (m, 4H), 7.19 (d, $J = 8.1$ Hz, 2H), 7.63 (d, $J = 8.4$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.7, 21.1, 21.5, 23.1, 31.9, 61.3, 126.6, 127.3, 129.3, 129.5, 136.1, 137.4, 138.1, 138.9, 141.7, 143.2, 203.2. IR (neat): 3240, 2920, 2837, 1655, 1428, 1334, 1164 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{14}\text{H}_{18}\text{NO}$ ($\text{M}-\text{Ts}^+$): 216.1388; found 216.1387.

Compound 3n. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.83 (t, $J = 7.2$ Hz, 3H), 0.91 (t, $J = 7.5$ Hz, 3H), 1.04–1.22 (m, 6H), 1.25–1.36 (m, 2H), 1.96–2.17 (m, 4H), 2.27 (s, 3H), 2.38 (s, 3H), 5.09 (d, $J = 8.7$ Hz, 1H), 5.61 (t, $J = 7.5$ Hz, 1H), 5.72 (d, $J = 8.7$ Hz, 1H), 6.98–7.02 (m, 4H), 7.19 (d, $J = 8.1$ Hz, 2H), 7.64 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.8, 14.1, 21.1, 21.5, 22.5, 23.0, 23.6, 28.7, 31.6, 44.1, 61.3, 126.8, 127.3, 129.3, 129.5, 136.0, 137.4, 137.1, 139.4, 139.5, 143.2, 206.8. IR (neat): 3297, 1658, 1512, 1418, 1339, 1161 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{28}\text{NO}$ ($\text{M}-\text{Ts}^+$): 286.2171; found 286.2166.

Compound 3o. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.80 (t, $J = 7.5$ Hz, 3H), 1.70 (m, 2H), 2.41 (s, 3H), 3.75 (s, 3H), 5.21 (d, $J = 7.5$ Hz, 1H), 5.82 (t, $J = 7.5$ Hz, 1H), 6.03 (d, $J = 7.5$ Hz, 1H), 6.74 (d, $J = 8.7$ Hz, 2H), 7.12 (d, $J = 8.7$ Hz, 2H), 7.22 (d, $J = 8.1$ Hz, 2H), 7.38 (t, $J = 7.5$ Hz, 2H), 7.53 (d, $J = 7.5$ Hz, 1H), 7.65 (d, $J = 7.5$ Hz, 2H), 7.71 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.5, 23.3, 55.2, 61.2, 113.9, 127.2, 128.2, 128.5, 129.1, 129.4, 130.9, 133.4, 137.1, 137.5, 137.8, 138.0, 143.1, 159.0, 199.1. IR (neat): 3215, 1633, 1511, 1436, 1330, 1243, 1158 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{20}\text{NO}_2$ ($\text{M}-\text{Ts}^+$): 294.1494; found 294.1493.

Compound 3p. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.74 (t, $J = 7.5$ Hz, 3H), 1.60–1.74 (m, 2H), 2.35 (s, 3H), 3.70 (s, 3H), 3.82 (s, 3H), 5.11 (d, $J = 7.5$ Hz, 1H), 5.65 (t, $J = 7.5$ Hz, 1H), 6.04 (d, $J = 7.5$ Hz, 1H), 6.67 (d, $J = 8.4$ Hz, 2H), 6.79 (d, $J = 8.7$ Hz, 2H), 7.07 (d, $J = 8.7$ Hz, 2H), 7.16 (d, $J = 8.1$ Hz, 2H), 7.58 (d, $J = 8.7$ Hz, 2H), 7.65 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.4, 23.2, 55.2, 55.5, 61.5, 113.78, 113.80, 127.2, 128.1, 129.4, 130.3, 130.9, 131.7, 136.8, 137.0, 137.9, 143.0, 158.9, 164.0, 197.6. IR (neat): 3278, 1600, 1509, 1421, 1341, 1253, 1161, 1094 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{20}\text{H}_{22}\text{NO}_3$ ($\text{M}-\text{Ts}^+$): 324.1600; found 324.1598.

Compound 3q. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.78 (t, $J = 7.5$ Hz, 3H), 1.63–1.79 (m, 2H), 2.39 (s, 3H), 3.73 (s, 3H), 5.18 (d, $J = 8.1$ Hz, 1H), 5.81 (t, $J = 7.8$ Hz, 1H), 6.03 (d, $J = 8.1$ Hz, 1H), 6.70 (d, $J = 8.4$ Hz, 2H), 7.05 (d, $J = 8.4$ Hz, 2H), 7.18 (d, $J = 8.1$ Hz, 2H), 7.47–7.51 (m, 4H), 7.66 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.3, 21.5, 23.3, 55.2, 60.9, 113.9, 127.2, 128.2, 128.8, 129.4, 130.6, 130.7, 131.9, 136.2, 137.0, 137.7, 137.9, 143.2, 159.1, 198.0. IR (neat): 3313, 2929, 1635, 1581, 1510, 1399, 1340, 1252 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{19}\text{NO}_2\text{Br}$ ($\text{M}-\text{Ts}^+$): 372.0599; found 372.0598.

Compound 3r. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.94 (t, $J = 7.5$ Hz, 3H), 2.05 (s, 3H), 2.14 (m, 2H), 2.39 (s, 3H), 3.75 (s, 3H), 5.10 (d, $J = 8.7$ Hz, 1H), 5.65 (d, $J = 8.7$ Hz, 1H), 5.73 (t, $J = 7.5$ Hz, 1H), 6.73 (d, $J = 8.7$ Hz, 2H), 7.03 (d, $J = 8.7$ Hz, 2H), 7.21 (d, $J = 8.1$ Hz, 2H), 7.64 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.8, 21.6, 23.1, 31.9, 55.4, 61.0, 114.0, 127.3, 128.0, 129.5, 131.2, 138.1, 139.1, 141.3, 143.2, 159.1, 203.4. IR (neat): 3284, 1660, 1608, 1511, 1424, 1335, 1249 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{14}\text{H}_{18}\text{NO}_2$ ($\text{M}-\text{Ts}^+$): 232.1338; found 232.1342.

Compound 3s. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.76 (t, $J = 7.5$ Hz, 3H), 1.60–1.70 (m, 2H), 2.39 (s, 3H), 3.85 (s, 3H), 2.17 (d, $J = 7.5$ Hz, 1H), 5.66 (t, $J = 7.8$ Hz, 1H), 6.30 (d, $J = 7.5$ Hz, 1H), 6.83 (d, $J = 9.0$ Hz, 2H), 7.13–7.17 (m, 4H), 7.19 (d, $J = 8.1$ Hz, 2H), 7.58 (d, $J = 8.7$ Hz, 2H), 7.66 (d, $J = 8.1$ Hz, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.2, 21.5, 23.4, 55.6, 61.6, 113.9, 127.2, 128.3, 128.6, 129.5, 131.7, 132.2, 133.4, 136.3, 137.5, 137.8, 138.0, 143.3, 164.2, 197.3. IR (neat): 3278, 1647, 1596, 1491, 1421, 1334, 1258 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{19}\text{NO}_2\text{Cl}$ ($\text{M}-\text{Ts}^+$): 328.1104; found 328.1099.

Compound 3t. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.76 (t, $J = 7.5$ Hz, 3H), 1.63–1.73 (m, 2H), 2.38 (s, 3H), 5.15 (d, $J = 7.8$ Hz, 1H), 5.75 (t, $J = 7.8$ Hz, 1H), 5.97 (d, $J = 7.8$ Hz, 1H), 6.99–7.26 (m, 8H), 7.56–7.65 (m, 4H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.2, 21.5, 23.5, 61.2, 115.8, 116.1, 127.2, 128.4, 129.1, 129.5, 131.8, 132.0, 133.6, 136.4, 137.3, 137.7, 138.8, 143.5, 197.2. IR (KBr): 3303, 1625, 1605, 1510, 1421, 1385, 1342, 1253 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{18}\text{H}_{16}\text{NOFCl}$ ($\text{M}-\text{Ts}^+$): 318.0885; found 318.0882.

Compound 3u. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.74 (t, $J = 7.5$ Hz, 3H), 1.56–1.75 (m, 2H), 2.36 (s, 6H), 5.52 (d, $J = 7.5$ Hz, 1H), 5.58 (t, $J = 8.1$ Hz, 1H), 6.38 (d, $J = 7.5$ Hz, 1H), 7.03–7.22 (m, 6H), 7.27–7.35 (m, 2H), 7.49 (d, $J = 8.1$ Hz, 2H), 7.69 (d, $J = 8.4$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.2, 21.5, 21.8, 23.5, 58.9, 127.1, 127.3, 128.9, 129.1, 129.2, 129.3, 129.4, 129.5, 132.4, 134.3, 134.7, 136.0, 137.4, 138.7, 143.2, 144.8, 198.9. IR (neat): 3286, 1654, 1603, 1444, 1338, 1239, 1162 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{19}\text{H}_{19}\text{NOCl}$ ($\text{M}-\text{Ts}^+$): 312.1155; found 312.1152.

Compound 3v. ^1H NMR (300 MHz, CDCl_3) δ , ppm: 0.74 (t, $J = 7.5$ Hz, 3H), 1.60–1.71 (m, 2H), 2.34 (s, 3H), 5.49 (d, $J = 7.5$ Hz, 1H), 5.61 (t, $J = 7.5$ Hz, 1H), 6.15 (d, $J = 7.5$ Hz, 1H), 7.05–7.20 (m, 6H), 7.41–7.47 (m, 4H), 7.65 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ , ppm: 13.2, 21.5, 23.4, 58.9, 115.7, 116.0, 127.2, 127.4, 129.1, 129.2, 129.5, 129.6, 131.8, 131.9, 132.4, 134.2, 135.8, 137.4, 139.0, 143.3, 197.7. IR (neat): 3284, 1660, 1583, 1444, 1335, 1160 cm^{-1} . HRMS (EI) calcd. for $\text{C}_{18}\text{H}_{16}\text{NOClBr}$ ($\text{M}-\text{Ts}^+$): 376.0104; found 376.0107.

ACKNOWLEDGMENTS

We are grateful to the National Natural Science Foundation of China (20572104) and the program of New Century Excellent Talents in University (NCET) (060551) for financial support.

REFERENCES

1. Lee, V. J. In *Comprehensive Organic Synthesis*; B. M. Trost, I. Fleming (Eds.); Pergamon: Oxford, 1991; vol. 4, pp. 139–168.
2. Mori, M.; Kuroda, S.; Dekura, F. Formation of silazirconacyclopentene via zirconium–silene complex and alkyne. *J. Am. Chem. Soc.* **1999**, *121*, 5591–5592.
3. (a) Denmark, S. E.; Choi, J. Y. Highly stereospecific, cross-coupling reactions of alkenylsilacyclobutanes. *J. Am. Chem. Soc.* **1999**, *121*, 5821–5822; (b) Maezaki, N.; Sawamoto, H.; Yoshigami, R.; Suzuki, T.; Tanaka, T. Geometrically selective synthesis of functionalized β,β -disubstituted vinylic sulfoxides by Cu-catalyzed conjugate addition of organozinc reagents to 1-alkynyl sulfoxides. *Org. Lett.* **2003**, *5*, 1345–1347.
4. (a) Roth, F.; Gyax, P.; Frater, G. An intramolecular Baylis–Hillman reaction. *Tetrahedron Lett.* **1992**, *33*, 1045–1048; (b) Drewes, S. E.; Njamela, O. L.; Emslie, N.

- D.; Ramesar, N.; Field, J. S. Intramolecular Baylis–Hillman reaction: A pathway to substituted coumarins. *Synth. Commun.* **1993**, *23*, 2807–2815.
5. Reviews for the MBH reaction: (a) Basavaiah, D.; Darma, R. P.; Hyma, R. S. The Baylis–Hillman reaction: A novel carbon–carbon bond-forming reaction. *Tetrahedron* **1996**, *52*, 8001–8062; (b) Langer, P. New strategies for the development of an asymmetric version of the Baylis–Hillman reaction. *Angew. Chem. Int. Ed.* **2000**, *39*, 3049–3052; (c) Basavaiah, D.; Rao, A. J.; Satyanarayana, T. Recent advances in the Baylis–Hillman reaction and applications. *Chem. Rev.* **2003**, *103*, 811–892; (d) Kataoka, T.; Kinoshita, H. Chalcogenide–Lewis acid–mediated tandem Michael aldol reaction: An alternative to the Morita–Baylis–Hillman reaction and a new development. *Eur. J. Org. Chem.* **2005**, 45–58.
6. (a) Trost, B. M.; Pinkerton, A. B. A ruthenium-catalyzed three-component coupling to form (*E*)-vinyl chlorides. *J. Am. Chem. Soc.* **1999**, *121*, 1988–1989; (b) Trost, B. M.; Pinkerton, A. B. A mechanistic dichotomy leading to a ruthenium-catalyzed *cis*-addition for stereoselective formation of (*Z*)-vinyl bromides. *Angew. Chem. Int. Ed.* **2000**, *39*, 360–362.
7. Marino, J. P.; Linderman, R. J. Chemistry of substituted (α -carbethoxyvinyl)cuprates 2: Stereospecific olefin synthesis. *J. Org. Chem.* **1983**, *48*, 4621–4628.
8. (a) Wei, H. X.; Willis, S.; Li, G. Lewis acid–promoted carbonyl addition of lithium (α -carbalkoxyvinyl)cuprates to aldehydes provides a novel asymmetric synthesis of β,β -disubstituted α -(hydroxyalkyl)acrylates. *Tetrahedron. Lett.* **1998**, *39*, 8203–8206; (b) Wei, H. X.; Willis, S.; Li, G. *Z/E* selective synthesis of β,β -disubstituted and (*Z*)- β -monosubstituted Baylis–Hillman adducts via anionic additions of vinylcuprates to aldehydes. *Synth. Commun.* **1999**, *29*, 2959–2966.
9. (a) Wei, H. X.; Hook, J. D.; Fitzgerald, K. A.; Li, G. Asymmetric synthesis of β -monosubstituted and β,β -disubstituted *N*-(*p*-toluenesulfinyl)- α -(aminoalkyl)acrylates via anionic additions of (α -carbalkoxyvinyl)cuprates to thiooxime *S*-oxides. *Tetrahedron: Asymmetry* **1999**, *10*, 661–665; (b) Li, G.; Wei, H. X.; Whittlesey, B. R.; Bartrice, N. N. Novel asymmetric C–C bond-formation process promoted by Et₂AlCl and its application to the stereoselective synthesis of unusual β -branched Baylis–Hillman adducts. *J. Org. Chem.* **1999**, *64*, 1061–1064; (c) Li, G.; Kim, S. H.; Wei, H. X. Highly efficient deprotection of *N-p*-toluenesulfinyl group of β -branched Baylis–Hillman adducts by using amberlite IR-120 (plus) ion-exchange resin. *Tetrahedron* **2000**, *56*, 719–723.
10. (a) Ramachandran, P. V.; Reddy, M. V. R.; Rudd, M. T.; Alaniz, J. R. Vinylalumination of fluoro-carbonyl compounds. *Tetrahedron Lett.* **1998**, *39*, 8791–8794; (b) Ramachandran, P. V.; Ram Reddy, M. V.; Rudd, M. T. Vinylalumination of activated carbonyl compounds. *Tetrahedron Lett.* **1999**, *40*, 627–630; (c) Ramachandran, P. V.; Ram Reddy, M. V.; Rudd, M. T. An improved vinylalumination procedure replacing HMPA with NMO for the hydroalumination of α -acetylenic esters and ketones. *Chem. Commun.* **1999**, 1979–1980; (d) Li, G.; Wei, H. X.; Willis, S. A new stereospecific synthesis of unusual (*Z*)- β -branched Baylis–Hillman adducts. *Tetrahedron Lett.* **1998**, *39*, 4607–4610; (e) Chen, D. J.; Timmons, C.; Liu, J. Y.; Hendley, A.; Li, G. The first enantioselective halo aldol reaction of ethyl propiolate and aldehydes. *Eur. J. Org. Chem.* **2004**, 3330–3335.
11. For conjugate addition of zinc–copper reagents to acetylenic esters, see (a) Knochel, P.; Singer, R. D. Preparation and reactions of polyfunctional organozinc reagents in organic synthesis. *Chem. Rev.* **1993**, *93*, 2117–2188; (b) Knoess, H. P.; Furlong, M. T.; Rozema, M. J.; Knochel, P. Preparation and reactions of zinc and copper organometallics bearing acidic hydrogens. *J. Org. Chem.* **1991**, *56*, 5974–5978; (c) Jubert, C.; Knochel, P. Preparation of new classes of aliphatic, allylic, and benzylic zinc and copper reagents by the insertion of zinc dust into organic halides, phosphates, and sulfonates. *J. Org. Chem.* **1992**, *57*, 5425–5431.

12. For conjugate addition of organozinc reagents to acetylenic ketones, see (a) Brunner, M.; Maas, G. Conjugate addition-reactions of functionalized organozinc and copper reagents to (2-propynylidene)morpholinium triflates. *Synthesis* **1995**, 957–963; (b) Nakamura, E.; Kuwajima, I. Copper-catalyzed acylation and conjugate addition of zinc homoenolate: Synthesis of 4- and 5-oxo esters. *J. Am. Chem. Soc.* **1984**, *106*, 3368–3370.
13. (a) Xue, S.; He, L.; Han, K. Z.; Liu, Y. K.; Guo, Q. X. Stereoselective synthesis of β -branched Baylis–Hillman adducts via organozinc species. *Synlett* **2005**, *8*, 1247–1250; (b) Xue, S.; He, L.; Liu, Y. K.; Guo, Q. X. An efficient CuI-promoted synthesis of tri- and tetra-substituted alkenes using organozinc species. *Synthesis* **2006**, 666–674.
14. Lorenz, J. C.; Jiang, L.; Yang, Z. Q.; Xue, S.; Xie, Y. N.; Shi, Y. A novel class of tunable zinc reagents (RXZnCH₂Y) for efficient cyclopropanation of olefins. *J. Org. Chem.* **2004**, *69*, 327–334.
15. Kitamura, M.; Miki, T.; Noyori, R. 1,4-Addition of diorganozincs to α,β -unsaturated ketones catalyzed by a copper(I)-sulfonamide combined system. *Bull. Chem. Soc. Jpn.* **2000**, *73*, 999–1014.
16. (a) Taniguchi, M.; Hino, T.; Kishi, Y. A practical synthesis of *trans*-iodoolefins. *Tetrahedron Lett.* **1986**, *27*, 4759–4762; (b) Kinoshita, S.; Kinoshita, H.; Iwamura, T.; Watanabe, S.; Kataoka, T. Chalcogenide–Lewis acid–mediated reactions of electron-deficient alkynes with aldehydes. *Chem. Eur. J.* **2003**, *9*, 1496–1502.

Copyright of Synthetic Communications is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.